

Northumbria Research Link

Citation: Wightman, Emma, Haskell, Crystal, Forster, Joanne, Veasey, Rachel and Kennedy, David (2012) Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. *Human Psychopharmacology: Clinical and Experimental*, 27 (2). pp. 177-186. ISSN 0885-6222

Published by: Wiley-Blackwell

URL: <http://dx.doi.org/10.1002/hup.1263> <<http://dx.doi.org/10.1002/hup.1263>>

This version was downloaded from Northumbria Research Link: <http://nrl.northumbria.ac.uk/5653/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)



Northumbria
University
NEWCASTLE

Epigallocatechin gallate (EGCG), cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation.

Journal:	<i>Human Psychopharmacology: Clinical and Experimental</i>
Manuscript ID:	HUP-11-0091.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	WIGHTMAN, EMMA; NORTHUMBRIA UNIVERSITY Haskell, Crystal; Northumbria University, Psychology Forster, Joanne; Northumbria University, Psychology Veasey, Rachel; Northumbria University, Psychology Kennedy, David; Northumbria University, Psychology
Keyword:	EGCG, Epigallocatechin gallate, Cerebral blood flow, Cognitive, Mood, NIRS

SCHOLARONE™
Manuscripts

Review

Epigallocatechin gallate (EGCG), cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation.

Emma. L. Wightman¹, Crystal. F. Haskell¹, Joanne. S. Forster¹, Rachel. C. Veasey¹, David. O. Kennedy¹.

¹Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle upon Tyne, United Kingdom, NE1 8ST.

Author for correspondence:

David. O. Kennedy

Brain, Performance and Nutrition Research Centre

Northumbria University

Newcastle, UK

NE1 8ST

Tel: (+44)191 2437720

Fax: (+44)191 2437820

e-mail: david.kennedy@northumbria.ac.uk

Running title: EGCG and cerebral blood flow

Clinicaltrials.gov ID: NCT00981292

Key Words: EGCG; epigallocatechin gallate; cerebral blood flow; cognitive, mood.

ABSTRACT

OBJECTIVE: To assess the effects of oral ingestion of the **green tea** polyphenol epigallocatechin gallate (EGCG) on cognitive performance, mood and localised cerebral blood flow (CBF) parameters in healthy human adults.

METHOD: In this double blind, placebo controlled, cross-over study 27 healthy adults received placebo and two doses (135 mg and 270 mg) of EGCG in counterbalanced order on separate days. Following a 45-min resting absorption period participants performed a selection of computerised cognitive tasks that activate the frontal cortex for a further 42 minutes. CBF and haemodynamics, as indexed by concentration changes in oxygenated and deoxygenated haemoglobin, were assessed in the frontal cortex throughout the post-treatment period using Near Infrared Spectroscopy (NIRS).

RESULTS: During the post-dose task performance period the administration of 135 mg EGCG resulted in reduced CBF in the frontal cortex, as indexed by significantly lower concentrations of both oxygenated and total haemoglobin, in comparison to placebo. Heart rate was significantly reduced from pre- to post dose across all treatments. No significant differences were observed for the level of deoxygenated haemoglobin or on any of the cognitive performance/mood measures.

CONCLUSIONS: These results demonstrate that a single dose of orally administered EGCG can modulate CBF parameters in healthy humans **but that this is not associated with changes in cognitive performance or mood.**

INTRODUCTION

Epigallocatechin gallate (EGCG) is the most abundant polyphenol found in the tea plant (*Camellia sinensis*), accounting for ~10% of the dry weight of green tea leaves (Mandel et al., 2008). Within the plant EGCG and other catechins confer protective and growth promoting roles, accumulating in vulnerable locations such as the seed coat, woody stem, root, and foliage (Forrest and Bendall, 1969). It has been suggested that the mechanisms by which tea catechins protect the host plant may also exert a range of protective health effects in the humans who consume **them** (Khan and Mukhtar, 2007), including possible protection against high blood cholesterol and high blood pressure (Taubert et al., 2007), and ischemic heart disease (Arts et al., 2001).

In vitro studies suggest that EGCG has a number of properties potentially relevant to brain function, including effects on cholinergic transmission (Katayama et al., 2002), neurite outgrowth (Reznichenko et al., 2005), inflammatory parameters (Kim et al., 2007), metal chelation (Mandel et al., 2008) and an ability to act as an anti-oxidant (Unno et al., 2007) and to up-regulate endogenous antioxidant capacity (Mandel et al., 2008). *In vivo* studies utilising animal models suggest that EGCG may offer multi-faceted protection against the aetiology and behavioural consequences of a number of neurodegenerative diseases **after oral administration**, including Alzheimer's disease (Koh et al., 2006; Lee et al., 2009; Rezai-Zadeh et al., 2008) and Parkinson's disease (Levites et al., 2001). **Epidemiological studies also suggest that tea consumption reduces the risk of ischemia/stroke in humans (Arab et al., 2009)** and green tea catechins (63% EGCG) have also been shown to improve cognitive

1
2
3
4 performance and concomitantly increase antioxidant capacity in normal rats **after oral**
5
6 **ingestion** (Haque et al., 2004).
7

8
9 One property underlying the potential cardio-vascular effects of EGCG is an ability to
10
11 modulate blood flow parameters. *Ex vivo* research in isolated rat aorta suggests that EGCG
12
13 exhibits vaso-relaxant properties (Lorenz et al., 2009; Chen et al., 2000; Alvarez et al., 2006).
14
15 However, vaso-constriction (Sanae et al., 2002; Shen et al., 2003) and biphasic relaxant and
16
17 constricting (Alvarez et al., 2004) properties have also been observed. Both the vaso-
18
19 relaxation and constriction have been attributed, in part, to opposite effects on endothelial
20
21 nitric oxide (NO) production and activity (Sanae et al., 2002; Lorenz et al., 2009). With
22
23 regards the effects of this in humans, a number of studies have demonstrated improved
24
25 endothelial function in the periphery following tea (Shenouda and Vita, 2007; Alexopoulos
26
27 et al., 2008; Nagaya et al., 2004) with similar effects seen following epicatechin
28
29 administered to healthy participants (Schroeter et al., 2006) and EGCG administered to
30
31 patients with coronary artery disease (Widlansky et al., 2007).
32
33
34
35
36
37

38 Whilst the balance of evidence suggests that EGCG promotes endothelial NO synthesis, and
39
40 therefore peripheral vaso-relaxation, it has also been shown to directly inhibit both
41
42 inducible NO synthase (iNOS) and neuronal NO synthase (nNOS) (Chan et al., 1997; Stevens
43
44 et al., 2002). While the effect of reducing neuronal NO production may confer
45
46 neuroprotective properties in the face of damaging overproduction of NO during brain
47
48 insults (Wei et al., 2004) the effects on cerebral blood flow (CBF) of EGCG related down-
49
50 regulation of nNOS during normal functioning are unknown. NO itself is a key vaso-dilatory
51
52 mediator in the neurovascular coupling of neuronal activity to increased blood supply in
53
54 active tissue (Gally et al., 1990; Kitaura et al., 2007) and whilst both eNOS and nNOS are
55
56
57
58
59
60

1
2
3
4 found in brain tissue (Toda and Okamura, 2003) it is NO derived from nNOS which has been
5
6 observed to make the greatest contribution to activity dependent vasodilation (Ayata et al.,
7
8 1996; Cholet et al., 1997; Kitaura et al., 2007; Santizo et al., 2000).

9
10
11 Indeed, previous *in vivo* research with the red wine polyphenol resveratrol indicates that as
12
13 well as up- regulating levels of eNOS (Tsai et al., 2007) resveratrol is also able to up- regulate
14
15 nNOS (Hung et al., 2004), **unlike EGCG**, and as such is associated with both peripheral
16
17 vasodilation (Rush et al., 2007; Rivera et al., 2009) and increased CBF in **the frontal cortex of**
18
19 healthy humans, as measured by Near Infrared Spectroscopy (NIRS), during the
20
21 performance of tasks that activate this brain region (Kennedy et al., 2010). **To date, a small**
22
23 **number of pharmacological intervention studies have also used the technique to infer**
24
25 **localized brain activity (Kanamaru et al., 2008) and CBF and oxygenation (Bönöczk et al.,**
26
27 **2002) from changes in haemoglobin concentrations. These include studies demonstrating**
28
29 **an increased haemodynamic response to task performance following docosahexaenoic**
30
31 **acid (Jackson et al., In press) and both increased CBF following single doses of resveratrol**
32
33 **(Kennedy et al., 2010) and decreased CBF following a single dose of caffeine (Kennedy and**
34
35 **Haskell, 2011).**

36
37
38 The current double-blind, placebo-controlled, balanced cross-over study therefore
39
40 investigated the effects of oral doses of EGCG on CBF in the frontal cortex using NIRS during
41
42 the performance of tasks that activate this brain region. Given the wide range of potential
43
44 brain relevant parameters that might be modulated by EGCG, including blood flow and
45
46 therefore the delivery of metabolic substrates, cognitive performance was also assessed
47
48 during the selection of executive function/working memory and attention tasks. **Heart rate**
49
50 **and blood pressure were also monitored at several time points throughout the study.**
51
52
53
54
55
56
57
58
59
60

EXPERIMENTAL METHODS

Participants

Twenty-seven healthy adults (11 males, 16 females, mean age 22 years, range 18-30, 23 right handed, 4 left handed) took part in the study. A further 5 participants that failed to satisfactorily complete the testing procedures were replaced during the running of the study and prior to un-blinding. All participants attended the laboratory having fasted from 2 hours prior to testing. Participants were required to consume a standardised diet prior to that in terms of what and when they ate on day 1. They abstained from caffeine and alcohol from 8pm the night before. All participants reported themselves to be in good health and free from social drugs, alcohol, prescription medication and herbal extracts/food supplements at each assessment. Participants who had suffered a head injury, neurological disorder or neuro-developmental disorder were excluded from participation, as were those who had any relevant food allergies or intolerances, smoked tobacco, drank excessive amounts of caffeine (more than 600mg day as assessed by a caffeine consumption questionnaire) or took illicit social drugs.

The study received ethical approval from the Northumbria University School of Psychology and Sport Sciences Ethics Committee and was conducted according to the Declaration of Helsinki (1964). All participants gave their informed consent prior to their inclusion in the study. **Prior to data collection this investigation was registered on the clinicaltrials.gov website with the following identification number: NCT00981292.**

Treatments

During the three study visits participants received three single-dose treatments in an order dictated by random allocation to a counterbalancing (Latin Square) order.

The three treatments comprised two capsules each containing either 135 mg EGCG (94% pure EGCG plus 6% excipients - DSM Nutritional Products) or an inert placebo. The capsules were combined to give the following treatments:

- i) Inert placebo
- ii) 135mg EGCG
- iii) 270mg EGCG

As this study was the first to investigate the cognitive and CBF effects of EGCG in humans, the doses utilized here are exploratory but represent the quantity of EGCG one might expect to achieve from ~1.5- 3 cups of green tea respectively. This is based on the approximation that 1 cup of green tea will yield ~90mg EGCG (Wu and Wei, 2002).

The treatments were administered in identical size 0 gelatine capsules, which were prepared and coded by a third party who had no further involvement in any aspect of the study. No member of the investigational team was aware of the contents of the capsules until a blind-data review was completed.

Near Infrared spectroscopy (NIRS):

1
2
3
4 NIRS is a non-invasive brain imaging technique in which two nominal wavelengths of light
5
6 (~765 and 855 nm), which are differentially absorbed by oxygenated and deoxygenated
7
8 haemoglobin respectively, are introduced through the skull via a laser emitter and
9
10 measured, following transit through the upper surface of the cortex, by an optode placed at
11
12 a pre-set distance from the light source (4cm in this case). Relative changes in the
13
14 absorption of near infrared light were measured at a time resolution of 10 Hz using a 12
15
16 channel Oxymon system (Artinis Medical Systems B.V.). The differential path-length factor
17
18 was adjusted according to the age of the participant. Relative concentration changes in
19
20 haemoglobins were calculated by means of a modified Beer-Lambert law (Obrig and
21
22 Villringer, 2003) using the proprietary software. The concentration changes in the total
23
24 levels of haemoglobin (total-Hb) were derived by summing the concentration changes in
25
26 oxygenated (oxy-Hb) and deoxygenated (deoxy-Hb) haemoglobin. NIRS haemodynamic
27
28 parameters have previously been shown to correspond strongly with the functional
29
30 magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) signal (Huppert et
31
32 al., 2006; Steinbrink et al., 2005). NIRS has been used extensively as a technique for
33
34 multiple-channel imaging of task related brain activity over relevant areas of the head
35
36 (Schecklmann et al., 2008), including in groups suffering from potential decrements in CBF
37
38 (Schecklmann et al., 2007).

39
40 In this study, given the extended recording period and the investigational aims, a simple two
41
42 emitter/optode pair configuration was utilised (i.e. 2 channels). The emitter/optode pairs
43
44 were positioned over the left and right frontal cortex using a standard optode holder
45
46 headband, which separated the pairs from each other by 4cm. Each pair therefore collected
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 data from an area of prefrontal cortex that included the areas corresponding to the
5
6 International 10-20 system Fp1 and Fp2 EEG positions.
7

8
9 The NIRS data output was time stamped at the start of each task segment to assure that
10
11 data corresponded to the relevant epoch of task performance.
12

13 14 15 16 17 **Cognitive tasks:**

18
19
20 In order to assess the contribution that activation of the brain region under investigation
21
22 made towards any treatment related effects on CBF, a selection of tasks that engender
23
24 either higher or lower activation of the frontal cortex were employed. **This paradigm was**
25
26 **adopted, in part, to assess the differential CBF effects elicited by task demand (with**
27
28 **frontal cortex CBF observed to increase with cognitive workload (Son et al., 2005;**
29
30 **Tsujimoto et al., 2004)) and how this interacted with treatment, but also in order to elicit**
31
32 **greater cognitive demand in the young participants employed here, who are presumably**
33
34 **at their cognitive peak. Thus any treatment related cognitive effects are liable to be subtle**
35
36 **and likely amplified under greater cognitive demand.** The 'low activation' tasks comprised
37
38 two simple reaction time tasks (Odd-ball reaction time and Simple reaction time). The 'high
39
40 activation' tasks (Serial subtractions, Rapid Visual Information Processing, and Stroop tasks)
41
42 all entail a higher cognitive workload and have all been shown to increase activity
43
44 specifically in the prefrontal cortex (Schroeter et al., 2002; Drummond et al., 1999; Bench et
45
46 al., 1993; Lawrence et al., 2002).
47
48
49
50
51
52
53
54
55

56 The computerised battery of cognitive tasks comprised:
57
58
59
60

1
2
3
4 **Serial subtractions:** This task (for further details see: (Kennedy et al., 2008)), **at baseline,**
5
6 **comprised 2 minutes of Serial 3s followed by 2 minutes of serial 7s subtractions with the**
7
8 **task length extending to 3.5 minutes for each task at post dose.** At the start of each
9
10 **subtraction task** a standard instruction screen informed the participant to mentally count
11
12 backwards in 3s or 7s, as quickly and accurately as possible, using the keyboard's linear
13
14 number keys to enter each response. Participants were also instructed verbally at the outset
15
16 that if they were to make a mistake they should carry on subtracting from the new incorrect
17
18 number. A random starting number between 800 and 999 was presented on the computer
19
20 screen, which was cleared by the entry of the first response. Each three-digit response was
21
22 represented on screen by an asterisk. Pressing the enter key signalled the end of each
23
24 response and cleared the three asterisks from the screen. Performance data (total number
25
26 of subtractions and number of errors) were calculated for the Serial 3s and 7s elements
27
28 separately. In the case of incorrect responses, subsequent responses were scored as
29
30 positive if they were correct in relation to the new number.
31
32
33
34
35
36

37 **Oddball reaction time task:** Two distinct visual stimuli (150 x 150 pixels) were presented on
38
39 screen at regular intervals. The frequent non-target stimuli (n = 200) were red circles and
40
41 the less frequent target stimuli (n = 40) were green squares. There was also an infrequent
42
43 distracter in the form of a blue triangle. The frequent and rare stimuli were randomly
44
45 presented during the task with each presentation consisting of a blank screen for 100 ms,
46
47 stimulus presentation for 100 ms and finally a blank screen for 1600 ms. During the task the
48
49 participants had to ignore frequent non-target stimuli and respond by pressing the 'space
50
51 bar' on a standard computer keyboard when the less-frequent target stimuli (**i.e. the green**
52
53
54
55
56
57
58
59
60

1
2
3
4 **square)** appeared. This task is scored for reaction time to target stimuli **and lasted ~3**
5
6 **minutes and 30 seconds at baseline and 7 minutes and 30 seconds at post dose.**
7
8

9 **Rapid Visual Information Processing task [RVIP]:** This task requires the participant to
10 monitor a continuous series of single digits for targets of three consecutive odd or three
11 consecutive even digits. The digits are presented on the computer screen at the rate of 100
12 per minute in pseudo-random order and the participant responds to the detection of a
13 target string by pressing the space bar as quickly as possible. The task is continuous and
14 lasted for 2 minutes at baseline and 7 minutes at post dose, with 8 correct target strings
15 being presented in each minute. The task is scored for number of target strings correctly
16 detected, average reaction time for correct detections, and number of false alarms.
17
18
19
20
21
22
23
24
25
26
27

28 **Stroop task:** Participants were required to complete a computerised version of the classic
29 Stroop task in which words describing colours (red, blue, yellow, green) were presented
30 either in the same 'congruent' font, or a different 'incongruent' font. Participants had to
31 identify the colour of the font that the word was written in, rather than the colour that the
32 word was describing, via a response box with coloured keys. For example, if the word red
33 appeared on the screen and was written in a blue font then the correct response would be
34 to press the blue key. **This task lasted for 2 minutes at baseline and 7 minutes at post dose.**
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The outcomes for the task were the number of correct responses and the average response times for congruent and incongruent stimuli.

Simple reaction time: The participant was instructed to continuously monitor the laptop screen and to press the space bar as quickly as possible every time a single stimulus (upwards pointing arrow) was presented. **The task length was 2 minutes at baseline and 7**

1
2
3
4 **minutes and post dose and** the task outcome was average reaction time (msec) response to
5
6 the stimuli.
7

8
9 **Mood Visual Analogue Scales (Mood VAS):** Prior to completing baseline and post dose tasks
10
11 participants were required to rate how 'relaxed', 'alert', 'jittery', 'tired', 'tense' and
12
13 'mentally fatigued' they felt by placing a cross with the mouse and cursor on a ~100mm on-
14
15 screen line between the descriptors 'not at all' and 'extremely'. They also rated their 'overall
16
17 mood' on a scale anchored by 'very poor' to 'very good' and their levels of 'headache'
18
19 between 'not at all' and 'extremely'. The VAS were scored as % along the line denoting more
20
21 of the relevant adjective.
22
23
24
25
26
27
28

29 **Procedure:**

30
31 Each participant was required to attend the laboratory on four occasions. The first of these
32
33 was an initial screening/training visit during which participants provided written informed
34
35 consent, were screened with regards the study exclusion/inclusion criteria, briefed with
36
37 regards compliance requirements, and given training in completing the cognitive tasks. This
38
39 visit was followed within 14 days by the first of three active study mornings.
40
41
42
43

44 On each of the three active study mornings, which were conducted 7 days apart,
45
46 participants attended the laboratory at 11:00am or 2:45pm having eaten nothing in the
47
48 preceding 2 hours and provided confirmation of continued compliance with the
49
50 inclusion/exclusion requirements. After a 5 minute seated resting period heart rate was
51
52 measured and a blood pressure reading was taken, after which participants completed
53
54 Mood VAS. Following a three minute resting period participants were verbally instructed to
55
56
57
58
59
60

1
2
3
4 start the period of baseline cognitive task performance which comprised shortened versions
5
6 of the cognitive tasks: Serial subtractions (3s - 2 mins, 7s - 2 mins); Oddball reaction time
7
8 task (3 minutes and 30 seconds); Stroop task (2 mins); Simple reaction time (2 mins) and
9
10 RVIP (2 mins). Participants then rested for 5 minutes after which they consumed their
11
12 treatment for that day, following which they sat quietly, watching one of a selection of non-
13
14 arousing DVDs, during a 45 minutes 'absorption' period. **The T_{max} of green tea polyphenols**
15
16 **varies hugely in the literature, ranging from 0.5- (Leenen et al., 2000; Pietta et al., 1998) to**
17
18 **4 hours (Nakagawa et al., 1997) depending on the form of catechin/s. Huge individual**
19
20 **variability in metabolism also influences T- and C_{max} . Thus, in the absence of consistent**
21
22 **bioavailability information, 45 minutes was chosen as a somewhat exploratory absorption**
23
24 **period.**

25
26
27
28
29
30 After completing the Mood VAS again participants were verbally instructed to start the
31
32 period of post dose task performance which comprised six 7 minute epochs of individual
33
34 task performance (plus up to an additional 30 seconds for those tasks that depended on
35
36 speed of response). The task order was Serial subtractions (3s then 7s - 3.5 minutes each),
37
38 Oddball reaction time task (7 minutes and 30 seconds), RVIP, Oddball reaction time task,
39
40 Stroop task, and then the Simple reaction time task (all 7 minutes) (i.e. ~ 42 minutes of
41
42 continuous task performance). After a 3 minute rest period heart rate was measured and a
43
44 blood pressure reading was taken from participants. NIRS data was captured throughout.
45
46
47
48
49 The timelines and running order of the testing session are shown in Figure 1.

50
51
52
53
54
55 **Figure 1 about here**
56
57
58
59
60

Statistics

The analyses of NIRS data were conducted with Minitab 15 for Windows (Minitab Inc, State College, PA) and behavioural data with SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). NIRS data was converted to 'change from baseline' (calculated from the final 3 minutes of the 5 minute resting period immediately pre-treatment) and data collected from the left and right hemispheres were averaged. Data from the 'resting/absorption' period (minutes 1 to 45) and the task performance period (minutes 46 to 87) were analyzed separately. Data from the 'resting/absorption' period was averaged across 6 equal 7.5 minute epochs and analysed by two-way repeated measures ANOVA (epoch x treatment). Data from the task period data was averaged across the 7 min task period, also giving 6 epochs, each of 7 minutes duration. This data was analysed by two-way repeated measures ANOVA (task [epoch] x treatment). In the case of those analyses that showed a significant main effect of treatment or a task/epoch x treatment interaction, planned comparisons of data from each task or epoch were then made between placebo and each of the EGCG treatment groups using t tests calculated with the Mean Squares Error from the ANOVA. A Bonferroni adjustment was made for multiplicity (Kepple, 1991). As the duration of each complete epoch of averaged NIRS data entered into the analysis was substantially longer than the potential physiological oscillations that can cause drift in shorter periods of NIRS recording (Hoshi, 2007) no adjustment was required to control for this phenomena.

Prior to the primary analyses, the distribution of the NIRS data was found to have a significant negative skew. The data was therefore normalised by inversion followed by a

1
2
3
4 Log(10) transformation. A further ANOVA was then conducted for each measure to confirm
5
6 that any significant differences found on the ANOVAs of raw data were retained following
7
8 normalisation.
9

10
11 Task performance data were analysed by within subjects ANCOVA (treatment) with pre-
12
13 treatment performance included as a co-variate for each individual task/measure (Serial 3s,
14
15 Serial 7s, RVIP, Stroop, Simple reaction time, Oddball and Mood VAS).
16

17
18 Blood pressure data (systolic, diastolic and heart rate) were analysed by within subjects
19
20 ANOVA (treatment x pre-post treatment).
21
22
23
24
25
26
27
28
29

30 **RESULTS**

31 32 **Cognitive performance and mood**

33
34
35 No significant treatment related differences were observed on any of the cognitive or mood
36
37 measures.
38
39

40 41 42 **Heart rate and blood pressure**

43
44
45
46 There was a significant reduction in heart rate across conditions between the initial pre-
47
48 dose measurement and the measurement taken at the end of testing (approximately 90
49
50 minutes post-dose) [$F(1, 26) = 8.15, p < 0.05$]. There was no interaction between treatment
51
52 and assessment ($F < 1$).
53
54
55
56
57
58
59
60

NIRS

Deoxygenated haemoglobin: There were no significant differences in terms of deoxy-Hb during either the resting or task performance periods.

Oxygenated haemoglobin: There was no effect of treatment during the absorption period. However, on the initial ANOVA, there was a significant main effect of treatment on oxy-Hb levels during the task period [$F(2, 52) = 3.41, p < 0.05$]. The analysis of normalised data confirmed that this effect survived log transformation [$F(2, 52) = 3.19, p < 0.05$]. Reference to the planned comparisons of the raw data means from each epoch showed that, whereas there were no significant differences associated with the higher dose of EGCG, the lower dose lead to a reduction in oxy-Hb during each of the six 7 minute task periods [$t's(260) = 4.83 - 5.84, all p < 0.01$].

Total levels of haemoglobin: Similarly, there was no effect of treatment on total-Hb during the absorption period. However, on the initial ANOVA, there was a significant main effect of treatment on total-Hb during the task period [$F(2, 52) = 3.53, p < 0.05$]. The analysis of normalised data confirmed that this effect survived log transformation [$F(2, 52) = 3.38, p < 0.05$]. Reference to the planned comparisons of the raw data means from each epoch showed that, whereas there were no significant differences associated with the higher dose of EGCG, the lower dose lead to a reduction in oxy-Hb during each of the six 7 minute task periods [$t's(260) = 4.96 - 6.85, all p < 0.01$].

There was no interaction between task and treatment with regards any of the NIRS parameters. A graphic representation of the mean total-Hb response to the first three

1
2
3
4 minutes of task performance (averaged across tasks) are shown in Figure 2. The mean
5
6 concentration changes (plus SEM) during the absorption and task periods for deoxy-Hb, and
7
8 total-Hb are shown in Figure 3.
9

10
11
12
13
14 **Figure 2 and Figure 3 about here**
15
16
17
18
19
20
21
22

23 **DISCUSSION**

24
25 The results here show that, in comparison to placebo, the consumption of EGCG resulted in
26
27 modulation of CBF parameters in the frontal cortex during task performance. This effect was
28
29 restricted to the lower (135 mg) dose of EGCG and was seen as a reduction in CBF during the
30
31 task period, as indexed by the concentration of haemoglobin (total-Hb), with an identical
32
33 pattern of results seen in terms of oxy-Hb. With regards deoxy-Hb, no effect of treatment
34
35 was observed. These CBF effects were not associated with any significant modulation of
36
37 either cognitive performance or mood and, whilst they were only evident during the task
38
39 performance period, there was no indication that the treatment related effects were
40
41 predicated on the amount of activation of the frontal cortex associated with the tasks that
42
43 were assumed to engender 'high' and 'low' activation of this brain region.
44
45
46
47
48

49
50 Whilst the results here show clearly that EGCG can modulate aspects of brain function, in
51
52 the absence of any modulation of behavioural parameters it is difficult to say whether the
53
54 comparative reduction in CBF seen here represents a net benefit or decrement in terms of
55
56 brain function. On the most simplistic level optimal performance should require increased
57
58
59
60

1
2
3
4 delivery of blood, and therefore metabolic substrates, during neuronal demand. **A recent**
5
6 **electroencephalography (EEG) study investigating the electrical brain response to EGCG in**
7
8 **healthy human participants, however, corresponds with the results presented in this**
9
10 **paper; finding that although 300mg orally consumed EGCG evinced increased cerebral**
11
12 **activity in the form of alpha, beta and theta waves, no task performance effects were**
13
14 **observed (Scholey et al., In press).**

15
16
17
18 Overall CBF has been shown to decline throughout adulthood (Parkes et al., 2004), and both
19
20 reduced basal CBF (Bertsch et al., 2009) and task specific CBF responses (Sorond et al., 2008)
21
22 are associated with declining performance during healthy ageing. Similarly, compromised
23
24 CBF has also been suggested as a key causal factor in the reduced cognitive function seen
25
26 with age and in a number of neurodegenerative diseases (Farkas et al., 2002). However,
27
28 whilst the reduced CBF seen here may therefore be interpreted as a detrimental effect it
29
30 may also reflect a reduced requirement for blood flow due to a further unidentified factor
31
32 improving other aspects of brain function. An alternative possibility is that the reduced CBF
33
34 might be negative in itself, but is compensated for by another, unmeasured mechanism. As
35
36 an example of this, caffeine is a vasoconstrictor that has been shown to reduce CBF as
37
38 assessed by a number of methods (Field et al., 2003; Lunt et al., 2004; Sigmon et al., 2009)
39
40 including the NIRS methodology employed here (Kennedy and Haskell, 2011). In the case of
41
42 caffeine the vasoconstriction is predicated on the blockade of adenosine A_{2A} receptors
43
44 throughout the cerebro-vascular system, whilst concomitant blockade of A₁ receptors
45
46 throughout the brain increases neuronal firing rate (Laurienti et al., 2003), leading
47
48 ultimately to net improvements in alertness and attention task performance despite
49
50 reduced CBF.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In terms of specific mechanisms underlying the effects seen here, it is interesting to note
5
6 that in a similar study we previously assessed the effects of single doses (250 mg, 500 mg) of
7
8 the polyphenol resveratrol in healthy human participants and observed a linear, dose-
9
10 related increase in CBF in the frontal cortex, during the performance of the mentally
11
12 demanding, 'frontal' Serial subtraction and RVIP tasks (Kennedy et al., 2010). The opposite
13
14 effect on CBF seen here following EGCG may well be related to differential effects on the
15
16 vaso-relaxatory process associated with NOS. In the case of resveratrol, evidence suggests
17
18 that it increases NO synthesis via eNOS (Tsai et al., 2007) and nNOS (Hung et al., 2004) and
19
20 consequently has evinced consistent effects in terms of NO related peripheral vaso-dilation
21
22 in animals (Lekakis et al., 2005; Zou et al., 2003) and humans (Wong et al., 2011) and
23
24 increased CBF in rats (Lu et al., 2006) and humans (Kennedy et al., 2010). EGCG on the other
25
26 hand has a less clear cut pattern of effects on vascular/microvascular tone, with some
27
28 evidence of improved peripheral endothelial function in humans (Widlansky et al., 2007) but
29
30 demonstrations *ex vivo* of both vaso-constriction (Sanae et al., 2002) and dilation (Alvarez et
31
32 al., 2006). It has also been shown to up-regulate eNOS (Widlansky et al., 2007) but inhibit
33
34 nNOS (Lin and Lin, 1997). Whilst both eNOS and nNOS are both found in brain tissue (Toda
35
36 and Okamura, 2003), it is nNOS derived NO which has been observed to make the greatest
37
38 contribution to activity dependent vasodilation (Santizo et al., 2000). Interestingly, the nNOS
39
40 isoform has also recently been associated with peripheral vasodilatory responses (Melikian
41
42 et al., 2009) including that elicited by cognitive task performance (Stroop) in healthy human
43
44 participants (Seddon et al., 2008). EGCGs inhibition of this isoform might therefore underlie
45
46 the less than straightforward effects seen, both in terms of the literature pertaining to
47
48 peripheral vasodilation, and the potential cerebral vasoconstriction seen in the current study.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This same inconsistency may also explain the dose specific effect seen here. EGCG's effects
5
6 on vascular tone have been shown to differ both over time and with dose. So, for instance,
7
8 EGCG has been shown to have transient peripheral vasoconstricting effects, followed by
9
10 vasodilation (Alvarez et al., 2004), and animal data confirms that at low doses green tea
11
12 catechins have vasoconstricting properties (Shen et al., 2003) and that at higher doses they
13
14 induce vasorelaxation (Lorenz et al., 2004). Whilst the differential effects of EGCG on the
15
16 eNOS and nNOS isoforms makes it difficult to extrapolate CNS effects from the peripheral
17
18 data it may well be that the lowest dose has cerebral vasoconstriction properties that are
19
20 simply not seen at the higher dose, and that a further increase in dose may result in
21
22 increased CBF. Naturally these possibilities will need to be explored further, and it would be
23
24 prudent to investigate longer time courses and both lower and higher doses in order to
25
26 document the full profile of EGCG's vasoregulatory properties. Interestingly, the migraine
27
28 treatment Sumatriptan also functions via modulation of NO, demonstrating both
29
30 vasorelaxing and a vasoconstricting properties (Elhusseiny and Hamel, 2001), and does not
31
32 have a straightforward dose response profile (Fowler et al., 1991). It is also interesting to
33
34 note that evidence from dose ranging studies in humans shows that a wide range of
35
36 phytochemicals and herbal extracts have greater impacts on cognitive performance and
37
38 physiological parameters at lower, rather than higher, doses. Recent examples of such
39
40 findings from dose ranging studies include sage (Scholey et al., 2008; Tildesley et al., 2003),
41
42 **guaraná** (Haskell et al., 2007), cocoa- flavanols (Scholey et al., 2010) and ginseng (Reay et
43
44 al., 2005).

45
46
47 One aspect of the current study that was somewhat disappointing was the failure to
48
49 demonstrate clear, differential haemodynamic responses to the more demanding 'high
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 activation' and less demanding 'low activation' tasks, whereby the former might have been
5
6 expected to engender higher total-Hb and lower deoxy-Hb. This manipulation was included
7
8 to try to differentiate whether any treatment related effects on CBF parameters were
9
10 specifically related to the level of activation, and therefore NO driven increases in blood
11
12 flow requirements, of the brain region. However, there was no evidence of any
13
14 treatment/task interaction, and the main effect of EGCG on CBF would appear, from the
15
16 data here, to be a general one across tasks, irrespective of cognitive workload. Reference to
17
18 Figure 3 shows a simple pattern of declining concentrations of total-Hb throughout the task
19
20 period, irrespective of treatment. **This apparent lack of sensitivity to task intensity could be**
21
22 **as a consequence of only utilizing a 2 channel NIRS system, thus reducing spatial**
23
24 **resolution. Future studies might therefore consider using additional channels and**
25
26 **recording at other locations of the cortex to assess if supplementary regions are involved**
27
28 **in the completion of these tasks.**

29
30 **Task length and/or perception of demand/difficulty could also explain the lack of CBF**
31
32 **sensitivity to tasks.** Reference to the finer grained analysis shown in Figure 2, which
33
34 presents the total-Hb data (averaged across tasks) for the first three minutes of task
35
36 performance in 10 second epochs, shows that total-Hb underwent the expected increase
37
38 during the first minute of performing each task, but that this was followed by a gradual
39
40 decline throughout the remainder of each task. This does suggest that the overall pattern of
41
42 haemodynamic responses was due to the extended length of the tasks employed, and that
43
44 employing shorter, more demanding tasks may be a more effective approach to
45
46 engendering a long period of increased haemodynamic response. Alternatively, it is also
47
48 notable that heart rate fell significantly across all three conditions from pre-dose to 90
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 minutes post-dose and it is possible that this reflects a simple reduction in physiological
5
6 arousal between arriving at the laboratory and completing the assessment. Future research
7
8 using this method of assessing CBF might usefully include an extended rest period before
9
10 recording commences, with heart rate monitoring throughout.

11
12
13 One key issue regarding EGCG and other polyphenols is that of the low bioavailability of the
14
15 parent compound (Lee et al., 2002), which questions the relevance to humans of much of
16
17 the *in vitro* research conducted with concentrations of EGCG that would not be attainable
18
19 in mammals. The paradoxical finding of multifarious *in vivo* effects despite this poor
20
21 bioavailability suggests that the metabolites of EGCG (and other polyphenols) may be active
22
23 in their own right: the substantial amounts of two catechin metabolites (4'-O- MeEGC, (-)-
24
25 5-(3', 4', 5'- trihydroxyphenyl) - γ - valerolactone (M4) and (-)-5-(3', 4'- dihydroxyphenyl) -
26
27 γ - valerolactone (M6)) detected in human plasma and urine would certainly suggest that
28
29 they could possess biological activities (Lee et al., 2002). Alternatively EGCG may operate
30
31 principally via secondary mechanisms, for instance NO synthesis, and as such only relatively
32
33 small concentrations may be required to instigate a cascade of cellular events. In this
34
35 respect it is interesting to note that EGCG has been shown to cross the blood-brain barrier
36
37 in rodents (Suganuma et al., 1998). Further research is certainly required to fully explore the
38
39 biotransformation of polyphenols in humans in order to better appreciate their sources of
40
41 bioactivity.

42
43
44 In conclusion, the results here demonstrate that the green tea catechin EGCG is able to
45
46 modulate CBF in healthy human participants, with decreased concentrations of
47
48 haemoglobin seen in the frontal cortex during cognitive task performance following the
49
50 lower (135 mg) of two doses that were administered. However, the lack of effects on
51
52
53
54
55
56
57
58
59
60

1
2
3
4 cognitive performance and mood make it difficult to interpret the modulation in CBF as
5
6 either a positive or negative modulation of overall brain function. With these results in
7
8 mind, future research might usefully investigate the effects of both lower and higher doses
9
10 of EGCG on both cerebral and peripheral blood flow. The combination of methodologies
11
12 may elucidate the comparative roles of eNOS and nNOS in any vaso-regulatory properties of
13
14 EGCG. **It would also be prudent to image other regions of the brain during the**
15
16 **performance of 'frontal' tasks and ascertain whether other areas of the brain are involved**
17
18 **and sharing the burden of increased workload.** Investigating the effects of longer
19
20 treatment periods and the behavioural/CBF effects of this polyphenol in cohorts that may
21
22 be more susceptible to modulation would also seem to be warranted by the current
23
24 investigation.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Author Statement:** None of the authors has any conflict of interests with regards the above
5
6 paper. This research received no specific grant from any funding agency in the public,
7
8 commercial or not-for-profit sectors. All materials were purchased on the open market. All
9
10 of the authors contributed to and reviewed the manuscript. DK and CH designed and
11
12 supervised the study. DK conducted the statistical analysis. JF and RV collected the data. EW
13
14 was the principal author.
15
16

17
18
19
20
21 **Abbreviations:** ANOVA - Analysis of Variance; BOLD - blood oxygen level dependent; CBF -
22
23 cerebral blood flow; deoxy-Hb - deoxygenated haemoglobin; EGCG - Epigallocatechin
24
25 gallate; eNOS - endothelial nitric oxide synthase; fMRI - functional magnetic resonance
26
27 imaging; iNOS - inducible nitric oxide synthase; NIRS - Near Infrared Spectroscopy; NO -
28
29 nitric oxide; nNOS - neuronal nitric oxide synthase; oxy-Hb - oxygenated haemoglobin; total-
30
31 Hb - total levels of haemoglobin; VAS - Visual Analogue Scales.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- Alexopoulos N, Vlachopoulos C, Aznaouridis K, et al. 2008. The acute effect of green tea consumption on endothelial function in healthy individuals. *European Journal of Cardiovascular Prevention & Rehabilitation* **15**: 300.
- Alvarez E, Campos M, Justiniano H, et al. 2006. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. *British journal of pharmacology*. **147**: 269-280.
- Alvarez E, Campos M, Orallo F. 2004. (-)-Epigallocatechin-3-gallate induces contraction of the rat aorta by a calcium influx-dependent mechanism. *Naunyn-Schmiedeberg's archives of pharmacology* **369**: 496-506.
- Arab L, Liu W, Elashoff D. 2009. Green and black tea consumption and risk of stroke: a meta-analysis. *Stroke* **40**: 1786.
- Arts ICW, Hollman PCH, Feskens EJM, et al. 2001. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. *American Journal of Clinical Nutrition* **74**: 227.
- Ayata C, Ma J, Meng W, et al. 1996. L-NA-sensitive rCBF augmentation during vibrissal stimulation in type III nitric oxide synthase mutant mice. *Journal of Cerebral Blood Flow & Metabolism* **16**: 539-541.
- Bench CJ, Frith CD, Grasby PM, et al. 1993. Investigations of the functional anatomy of attention using the Stroop test. *Neuropsychologia* **31**: 907-922.
- Bertsch K, Hagemann D, Hermes M, et al. 2009. Resting cerebral blood flow, attention, and aging. *Brain research* **1267**: 77-88.
- Bönöczk P, Panczel G, Nagy Z. 2002. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. *European Journal of Ultrasound* **15**: 85-91.
- Chan M, Fong D, Ho C, et al. 1997. Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. *Biochemical Pharmacology* **54**: 1281-1286.
- Chen Z, Law W, Yao X, et al. 2000. Inhibitory effects of purified green tea epicatechins on contraction and proliferation of arterial smooth muscle cells. *Acta pharmacologica Sinica* **21**: 835.
- Cholet N, Seylaz J, Lacombe P, et al. 1997. Local uncoupling of the cerebrovascular and metabolic responses to somatosensory stimulation after neuronal nitric oxide synthase inhibition. *Journal of Cerebral Blood Flow & Metabolism* **17**: 1191-1201.
- Drummond SPA, Brown GG, Stricker JL, et al. 1999. Sleep deprivation-induced reduction in cortical functional response to serial subtraction. *Neuroreport* **10**: 3745-3748.
- Elhusseiny A, Hamel E. 2001. Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles. *British journal of pharmacology* **132**: 55-62.
- Farkas E, de Wilde MC, Kiliaan AJ, et al. 2002. Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: window of treatment. *Drugs of today* **38**: 365-376.
- Field AS, Laurienti PJ, Yen YF, et al. 2003. Dietary Caffeine Consumption and Withdrawal: Confounding Variables in Quantitative Cerebral Perfusion Studies? 1. *Radiology* **227**: 129.
- Forrest GI, Bendall DS. 1969. The distribution of polyphenols in the tea plant (*Camellia sinensis* L.). *Biochem. J* **113**: 741-755.
- Fowler PA, Lacey LF, Thomas M, et al. 1991. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. *European neurology* **31**: 291-294.
- Gally JA, Montague PR, Reeke GN, et al. 1990. The NO hypothesis: possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous system. *Proceedings of the National Academy of Sciences of the United States of America* **87**: 3547.

- 1
2
3
4 Haque AM, Hashimoto M, Katakura M, et al. 2004. Long-term administration of green tea catechins
5 improves spatial cognition learning ability in rats. *International Conference on O-CHA(tea)*
6 *Culture and Science (ICOS)*. Amer Society Nutritional Science: Shizuoka, JAPAN.
- 7 Haskell CF, Kennedy DO, Wesnes KA, et al. 2007. A double-blind, placebo-controlled, multi-dose
8 evaluation of the acute behavioural effects of guarana in humans. *Journal of*
9 *Psychopharmacology* **21**: 65-70.
- 10 Hoshi Y. 2007. Functional near-infrared spectroscopy: current status and future prospects. *Journal of*
11 *Biomedical Optics* **12**: 062106.
- 12 Hung LM, Su MJ, Chen JK. 2004. Resveratrol protects myocardial ischemia-reperfusion injury through
13 both NO-dependent and NO-independent mechanisms. *Free Radical Biology and Medicine*
14 **36**: 774-781.
- 15 Huppert TJ, Hoge RD, Diamond SG, et al. 2006. A temporal comparison of BOLD, ASL, and NIRS
16 hemodynamic responses to motor stimuli in adult humans. *Neuroimage* **29**: 368-382.
- 17 Jackson PA, Scholey AB, Reay JL. In press. DHA-rich oil modulates the cerebral haemodynamic
18 response to cognitive tasks in healthy young adults: A Near Infrared Spectroscopy pilot
19 study. *British Journal of Nutrition*.
- 20 Kanamaru Y, Kikukawa A, Miyamoto Y, et al. 2008. Dimenhydrinate effect on cerebral oxygen status
21 and salivary chromogranin-A during cognitive tasks. *Progress in Neuro-Psychopharmacology*
22 *and Biological Psychiatry* **32**: 107-115.
- 23 Katayama Y, Homma T, Hara Y, et al. 2002. Tea catechin, (-)-epigallocatechin gallate, facilitates
24 cholinergic ganglion transmission in the myenteric plexus of the guinea-pig small intestine.
25 *Neuroscience Letters* **319**: 63-66.
- 26 Kennedy D, Haskell C, Robertson B, et al. 2008. Improved cognitive performance and mental fatigue
27 following a multi-vitamin and mineral supplement with added guarana (*Paullinia cupana*).
28 *Appetite* **50**: 506-513.
- 29 Kennedy DO, Haskell CF. 2011. Cerebral blood flow and behavioural effects of caffeine in habitual
30 and non-habitual consumers of caffeine: A Near Infrared Spectroscopy study. *Biological*
31 *Psychology*.
- 32 Kennedy DO, Wightman EL, Reay JL, et al. 2010. Effects of resveratrol on cerebral blood flow
33 variables and cognitive performance in humans: a double-blind, placebo-controlled,
34 crossover investigation. *American Journal of Clinical Nutrition* **91**: 1590-1597.
- 35 Kepple G. 1991. *Design and analysis*. Prentice Hall: New Jersey.
- 36 Khan N, Mukhtar H. 2007. Tea polyphenols for health promotion. *Life sciences* **81**: 519-533.
- 37 Kim SJ, Jeong HJ, Lee KM, et al. 2007. Epigallocatechin-3-gallate suppresses NF-kappa B activation
38 and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. *Journal of*
39 *Nutritional Biochemistry* **18**: 587-596.
- 40 Kitaura H, Uozumi N, Tohmi M, et al. 2007. Roles of nitric oxide as a vasodilator in neurovascular
41 coupling of mouse somatosensory cortex. *Neuroscience Research* **59**: 160-171.
- 42 Koh SH, Lee SM, Kim HY, et al. 2006. The effect of epigallocatechin gallate on suppressing disease
43 progression of ALS model mice. *Neuroscience Letters* **395**: 103-107.
- 44 Laurienti PJ, Field AS, Burdette JH, et al. 2003. Relationship between caffeine-induced changes in
45 resting cerebral perfusion and blood oxygenation level-dependent signal. *American Journal*
46 *of Neuroradiology* **24**: 1607.
- 47 Lawrence NS, Ross TJ, Stein EA. 2002. Cognitive mechanisms of nicotine on visual attention. *Neuron*
48 **36**: 539-548.
- 49 Lee M, Maliakal P, Chen L, et al. 2002. Pharmacokinetics of Tea Catechins after Ingestion of Green
50 Tea and (-)-Epigallocatechin-3-gallate by Humans. *Cancer Epidemiology Biomarkers &*
51 *Prevention* **11**: 1025.
- 52 Lee YK, Yuk DY, Lee JW, et al. 2009. (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-
53 induced elevation of beta-amyloid generation and memory deficiency. *Brain Research* **1250**:
54 164-174.
- 55
56
57
58
59
60

- 1
2
3
4 Leenen R, Roodenburg AJC, Tijburg LBM, et al. 2000. A single dose of tea with or without milk
5 increases plasma antioxidant activity in humans. *European Journal of Clinical Nutrition* **54**:
6 87-92.
- 7 Lekakis J, Rallidis LS, Andreadou I, et al. 2005. Polyphenolic compounds from red grapes acutely
8 improve endothelial function in patients with coronary heart disease. *European Journal of*
9 *Cardiovascular Prevention & Rehabilitation* **12**: 596.
- 10 Levites Y, Weinreb O, Maor G, et al. 2001. Green tea polyphenol (-)-epigallocatechin-3-gallate
11 prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic
12 neurodegeneration. *Journal of Neurochemistry* **78**: 1073-1082.
- 13 Lin YL, Lin JK. 1997. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by
14 down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor- κ B.
15 *Molecular pharmacology* **52**: 465-472.
- 16 Lorenz M, Urban J, Engelhardt U, et al. 2009. Green and black tea are equally potent stimuli of NO
17 production and vasodilation: new insights into tea ingredients involved. *Basic research in*
18 *cardiology* **104**: 100-110.
- 19 Lorenz M, Wessler S, Follmann E, et al. 2004. A constituent of green tea, epigallocatechin-3-gallate,
20 activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-
21 dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent
22 vasorelaxation. *Journal of Biological Chemistry* **279**: 6190.
- 23 Lu KT, Chiou RYY, Chen LG, et al. 2006. Neuroprotective effects of resveratrol on cerebral ischemia-
24 induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation.
25 *J. Agric. Food Chem* **54**: 3126-3131.
- 26 Lunt MJ, Ragab S, Birch AA, et al. 2004. Comparison of caffeine-induced changes in cerebral blood
27 flow and middle cerebral artery blood velocity shows that caffeine. *Physiological*
28 *Measurement* **25**: 467-474.
- 29 Mandel SA, Amit T, Weinreb O, et al. 2008. Simultaneous Manipulation of Multiple Brain Targets by
30 Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson
31 Diseases. *Cns Neuroscience & Therapeutics* **14**: 352-365.
- 32 Melikian N, Seddon MD, Casadei B, et al. 2009. Neuronal Nitric Oxide Synthase and Human Vascular
33 Regulation. *Trends in Cardiovascular Medicine* **19**: 256-262.
- 34 Nagaya N, Yamamoto H, Uematsu M, et al. 2004. Green tea reverses endothelial dysfunction in
35 healthy smokers. *Heart* **90**: 1485.
- 36 Nakagawa K, Okuda S, Miyazawa T. 1997. Dose-dependent incorporation of tea catechins,(-)-
37 epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. *Bioscience,*
38 *biotechnology, and biochemistry* **61**: 1981-1985.
- 39 Obrig H, Villringer A. 2003. Beyond the visible - Imaging the human brain with light. *Journal of*
40 *Cerebral Blood Flow and Metabolism* **23**: 1-18.
- 41 Parkes LM, Rashid W, Chard DT, et al. 2004. Normal cerebral perfusion measurements using arterial
42 spin labeling: reproducibility, stability, and age and gender effects. *Magnetic Resonance in*
43 *Medicine* **51**: 736-743.
- 44 Pietta PG, Simonetti P, Gardana C, et al. 1998. Catechin metabolites after intake of green tea
45 infusions. *Biofactors* **8**: 111-118.
- 46 Reay J, Kennedy D, Scholey A. 2005. Single doses of Panax ginseng (G115) reduce blood glucose
47 levels and improve cognitive performance during sustained mental activity. *Journal of*
48 *Psychopharmacology* **19**: 357.
- 49 Rezai-Zadeh K, Arendash GW, Hou H, et al. 2008. Green tea epigallocatechin-3-gallate (EGCG)
50 reduces [beta]-amyloid mediated cognitive impairment and modulates tau pathology in
51 Alzheimer transgenic mice. *Brain Research* **1214**: 177-187.
- 52 Reznichenko L, Amit T, Youdim MBH, et al. 2005. Green tea polyphenol (-)-epigallocatechin-3-gallate
53 induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite
54 outgrowth. *Journal of Neurochemistry* **93**: 1157-1167.
- 55
56
57
58
59
60

- 1
2
3
4 Rivera L, Morón R, Zarzuelo A, et al. 2009. Long-term resveratrol administration reduces metabolic
5 disturbances and lowers blood pressure in obese Zucker rats. *Biochemical Pharmacology* **77**:
6 1053-1063.
- 7 Rush JWE, Quadriatero J, Levy AS, et al. 2007. Chronic resveratrol enhances endothelium-dependent
8 relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats.
9 *Experimental Biology and Medicine* **232**: 814-822.
- 10 Sanae F, Miyaichi Y, Kizu H, et al. 2002. Effects of catechins on vascular tone in rat thoracic aorta
11 with endothelium. *Life sciences* **71**: 2553-2562.
- 12 Santizo R, Baughman VL, Pelligrino DA. 2000. Relative contributions from neuronal and endothelial
13 nitric oxide synthases to regional cerebral blood flow changes during forebrain ischemia in
14 rats. *Neuroreport* **11**: 1549.
- 15 Schecklmann M, Ehliis A-C, Plichta MM, et al. 2007. Altered frontal brain oxygenation in detoxified
16 alcohol dependent patients with unaffected verbal fluency performance. *Psychiatry*
17 *Research: Neuroimaging* **156**: 129-138.
- 18 Schecklmann M, Ehliis AC, Plichta MM, et al. 2008. Functional near-infrared spectroscopy: A long-
19 term reliable tool for measuring brain activity during verbal fluency. *Neuroimage* **43**: 147-
20 155.
- 21 Scholey A, Downey LA, Ciorciari J, et al. In press. Acute neurocognitive effects of epigallocatechin
22 gallate (EGCG). *Human psychopharmacology*.
- 23 Scholey AB, French SJ, Morris PJ, et al. 2010. Consumption of cocoa flavanols results in acute
24 improvements in mood and cognitive performance during sustained mental effort. *Journal*
25 *of Psychopharmacology* **24**: 1505.
- 26 Scholey AB, Tildesley NTJ, Ballard CG, et al. 2008. An extract of Salvia (sage) with anticholinesterase
27 properties improves memory and attention in healthy older volunteers.
28 *Psychopharmacology* **198**: 127-139.
- 29 Schroeter H, Heiss C, Balzer J, et al. 2006. (-)-Epicatechin mediates beneficial effects of flavanol-rich
30 cocoa on vascular function in humans. *Proceedings of the National Academy of Sciences* **103**:
31 1024.
- 32 Schroeter ML, Zysset S, Kupka T, et al. 2002. Near-infrared spectroscopy can detect brain activity
33 during a color-word matching Stroop task in an event-related design. *Human brain mapping*
34 **17**: 61-71.
- 35 Seddon M, Chowienczyk P, Brett S, et al. 2008. Neuronal nitric oxide synthase regulates basal
36 microvascular tone in humans in vivo. *Circulation* **117**: 1991.
- 37 Shen JZ, Zheng XF, Wei EQ, et al. 2003. Green tea catechins evoke a phasic contraction in rat aorta
38 via H₂O₂-mediated multiple-signalling pathways. *Clinical and Experimental Pharmacology*
39 *and Physiology* **30**: 88-95.
- 40 Shenouda SM, Vita JA. 2007. Effects of flavonoid-containing beverages and EGCG on endothelial
41 function. *Journal of the American College of Nutrition* **26**: 366S.
- 42 Sigmon SC, Herning RI, Better W, et al. 2009. Caffeine withdrawal, acute effects, tolerance, and
43 absence of net beneficial effects of chronic administration: cerebral blood flow velocity,
44 quantitative EEG, and subjective effects. *Psychopharmacology* **204**: 573-585.
- 45 Son IY, Guhe M, Gray W, et al. 2005. Human performance assessment using fNIR. *Proceedings of*
46 *SPIE: Biomonitoring for physiological and cognitive performance during military operations*.
47 Citeseer:
- 48 Sorond FA, Schnyer DM, Serrador JM, et al. 2008. Cerebral blood flow regulation during cognitive
49 tasks: Effects of healthy aging. *Cortex* **44**: 179-184.
- 50 Steinbrink J, Villringer A, Kempf F, et al. 2005. Illuminating the BOLD signal: combined fMRI-fNIRS
51 studies. *International School on Magnetic Resonance and Brain Function*. Erice, ITALY.
- 52 Stevens J, Miranda C, Wolthers K, et al. 2002. Identification and in vitro biological activities of hop
53 proanthocyanidins: inhibition of nNOS activity and scavenging of reactive nitrogen species. *J*
54 *Agric. Food Chem* **50**: 3435-3443.
- 55
56
57
58
59
60

- 1
2
3
4 Suganuma M, Okabe S, Oniyama M, et al. 1998. Wide distribution of [3H](-)-epigallocatechin gallate,
5 a cancer preventive tea polyphenol, in mouse tissue. *Carcinogenesis* **19**: 1771.
6 Taubert D, Roesen R, Schomig E. 2007. Effect of cocoa and tea intake on blood pressure: a meta-
7 analysis. *Archives of internal medicine* **167**: 626.
8 Tildesley NTJ, Kennedy DO, Perry EK, et al. 2003. Salvia lavandulaefolia (Spanish Sage) enhances
9 memory in healthy young volunteers. *Pharmacology Biochemistry and Behavior* **75**: 669-674.
10 Toda N, Okamura T. 2003. The pharmacology of nitric oxide in the peripheral nervous system of
11 blood vessels. *Pharmacological reviews* **55**: 271.
12 Tsai SK, Hung LM, Fu YT, et al. 2007. Resveratrol neuroprotective effects during focal cerebral
13 ischemia injury via nitric oxide mechanism in rats. *Journal of Vascular Surgery* **46**: 346-353.
14 Tsujimoto S, Yamamoto T, Kawaguchi H, et al. 2004. Prefrontal cortical activation associated with
15 working memory in adults and preschool children: an event-related optical topography
16 study. *Cerebral Cortex* **14**: 703-712.
17 Unno K, Takabayashi F, Yoshida H, et al. 2007. Daily consumption of green tea catechin delays
18 memory regression in aged mice. *Biogerontology* **8**: 89-95.
19 Wei I, Wu Y, Wen C, et al. 2004. Green tea polyphenol (-)-epigallocatechin gallate attenuates the
20 neuronal NADPH-d/nNOS expression in the nodose ganglion of acute hypoxic rats. *Brain*
21 *Research* **999**: 73.
22 Widlansky ME, Hamburg NM, Anter E, et al. 2007. Acute EGCG supplementation reverses endothelial
23 dysfunction in patients with coronary artery disease. *Journal of the American College of*
24 *Nutrition* **26**: 95.
25 Wong RHX, Howe PRC, Buckley JD, et al. 2011. Acute resveratrol supplementation improves flow-
26 mediated dilatation in overweight/obese individuals with mildly elevated blood pressure.
27 *Nutrition, Metabolism and Cardiovascular Diseases* **21**: 851-856.
28 Wu CD, Wei GX. 2002. Tea as a functional food for oral health. *Nutrition* **18**: 443.
29 Zou JG, Wang ZR, Huang YZ, et al. 2003. Effect of red wine and wine polyphenol resveratrol on
30 endothelial function in hypercholesterolemic rabbits. *International journal of molecular*
31 *medicine* **11**: 317-320.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figures:




Figure 1. Timelines of each assessment. Blood pressure and heart rate were measured.

Participants then completed one repetition of the tasks to establish baseline performances.

After a 5 minute resting period, they received their day's treatment and, after a 45 minute resting/absorption period, they completed a longer version of each of the baseline tasks.

After completion heart rate and blood pressure were measured again. Near- infrared spectroscopy (NIRS) data were collected throughout with the pre-treatment resting phase used to baseline- adjust all pre-treatment data.




Figure 2. Total-Hb data, averaged across the tasks, and shown for the first three minutes of task performance in 10 second epochs.

Peer Review




Figure 3. Mean (plus SEM) changes in concentrations of deoxy-Hb and Total-Hb during the absorption period and six 7 minute task periods (** = $p < 0.01$, Bonferroni adjusted planned comparisons).